title: It's about time--directing our attention toward modifying the course of COPD.
abstract: The course of COPD has traditionally been equated with an accelerated decline in the forced expiratory volume in one second (FEVi) over time in patients with COPD, compared to healthy individuals. However, other important clinical outcomes associated with COPD also worsen over time and should also be considered in conceptualizing the course of COPD. These include health status, breathlessness related to activities of daily living, exercise capacity, the frequency of exacerbations, and peripheral muscle weakness. These outcomes are often quite responsive to therapy of COPD. Presently there is no evidence that any treatment other than smoking cessation can normalise the rate of decline of FEVi, and therefore be considered as modifying the physiologic course of the disease. Thus, smoking cessation reigns as the primary disease modifying strategy in COPD. Even though there are a number of smoking cessation products on the market and smoking prevalence continues to decrease marginally each year, more needs to be done to provide comprehensive programmes to help people quit smoking. In the US in 2004, 37.5% of preventable deaths were found to be tobacco-related. The FEVi does not reflect the clinical manifestations or the total burden of this multidimensional illness. As novel therapeutic agents become available that may alter the underlying pathology of COPD, additional markers and outcomes of disease progression will be needed to provide a more comprehensive assessment. There has been increasing interest in predicting and assessing mortality as it is the final outcome of disease progression. In this review we have considered three approaches toward modifying the course of COPD: smoking cessation, reduction in lung hyperinflation through medical and surgical approaches, and long-term pharmacotherapy.
authors.affiliation: University of Rome Tor Vergata, Department of Internal Medicine, Unit of Respiratory Diseases, Rome, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.forename: Nicola A
authors.initials: NA
authors.lastname: Hanania
authors.forename: Paul W
authors.initials: PW
authors.lastname: Jones
authors.forename: Donald A
authors.initials: DA
authors.lastname: Mahler
authors.forename: Barry
authors.initials: B
authors.lastname: Make
authors.forename: Jill
authors.initials: J
authors.lastname: Ohar
authors.forename: Stephen
authors.initials: S
authors.lastname: Rennard
mesh_terms: D001993:Bronchodilator Agents / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005541:Forced Expiratory Volume / Q000502:physiology; D006304:Health Status; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D011788:Quality of Life / Q000523:psychology; D016032:Randomized Controlled Trials as Topic; D016540:Smoking Cessation / Q000379:methods* / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D001993:Bronchodilator Agents